923032-74-0

Usage

Explanation

The compound's name is derived from its structure, indicating the presence of a benzene ring with two amine groups, fluorine and iodine atoms, and a methoxy group.

Explanation

The compound consists of a benzene ring with two nitrogen atoms (forming amine groups) attached to the 1 and 2 positions, a fluorine atom at the 3 and 4 positions, an iodine atom at the 4 position of the second phenyl group, and a methoxy group at the 6 position.

Explanation

The compound is a derivative of benzene, containing two amino groups, making it a diamine.

Explanation

The compound contains various functional groups, including two amino groups, fluorine and iodine atoms, and a methoxy group, which contribute to its reactivity and potential applications.

Explanation

The presence of electronegative fluorine and iodine atoms, as well as the methoxy group, makes the compound highly reactive, allowing it to participate in various chemical reactions.

Explanation

The compound's properties and potential uses can change based on the specific chemical reaction or application it is being used for, as different reactions may require different properties from the compound.

Structure

Aromatic ring with two amine groups, fluorine and iodine atoms, and a methoxy group.

Classification

Diamine derivative of benzene.

Functional Groups

Amino (-NH2), Fluorine (-F), Iodine (-I), and Methoxy (-OCH3).

Reactivity

Highly reactive due to the presence of fluorine, iodine, and methoxy groups.

Applications

Potentially useful in organic chemistry for various reactions and applications.

Context-Dependent Properties

Uses and properties may vary depending on the specific context and intended application.

Upstream product

• 923032-72-8 (2,3-difluoro-5-methoxy-6-nitro-phenyl)-(2-fluoro-4-iodo-phenyl)-amine 
• 765962-71-8 (2-fluoro-4-iodo-phenyl)-(2,3,5-trifluoro-6-nitro-phenyl)-amine 
• 314-41-0 1,2,3,5-tetrafluoro-4-nitrobenzene 
• 29632-74-4 2-fluro-4-iodoaniline 

Downstream Products

• 952417-04-8 2-(2,2-dimethyl-[1,3]dioxolan-4-yl)-methane-amino-sulfonic acid [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-6-methoxyl-phenyl]-amide 
• 923032-76-2 6,7-difluoro-1-(2-fluoro-4-iodo-phenyl)-4-methoxy-1H-benzo[d]imidazol-2(3H)-one 
• 923032-91-1 C₃₂H₅₀F₃IN₂O₅SSi₂ 
• 1311401-10-1 6,7-difluoro-1-(2-fluoro-4-iodophenyl)-4-methoxy-5-nitro-1,3-dihydrobenzoimidazol-2-one 
• 1311401-13-4 5-amino-6,7-difluoro-1-(2-fluoro-4-iodophenyl)-4-methoxy-1,3-dihydrobenzoimidazol-2-one 
• 1311401-19-0 5-amino-6,7-difluoro-1-(2-fluoro-4-iodophenyl)-4-hydroxy-1,3-dihydrobenzoimidazol-2-one 
• 1311401-28-1 4,5-difluoro-6-(2-fIuoro-4-iodophenyl)-6,8-dihydroimidazo[4',5':3,4]benzo[1,2-d]oxazol-7-one 
• 1311401-48-5 8-cyclopropanesulfonyl-4,5-difluoro-6-(2-fluoro-4-iodophenyl)-6,8-dihydroimidazo[4',5':3,4]benzo[1,2-d]oxazol-7-one 
• 1311400-85-7 cyclopropanesulfonic acid [4,5-difluoro-6-(2-fluoro-4-iodophenylamino)-benzooxazol-7-yl]amide 
• 923032-37-5 (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 
• 1262760-18-8 (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)cyclopropane-1-sulfonamide 
• 923032-37-5 Refametinib 
• 1262759-97-6 (R)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)prop-1-ene-2-sulfonamide 
• 1262759-98-7 (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-3-(2,2-dimethyl-1,3-dioxolan-4-yl)prop-1-ene-2-sulfonamide 

Relevant academic research and scientific papers

Continuous Platinum-Mediated Hydrogenation of Refametinib Iodo-nitroaniline Key Intermediate DIM-NA: The Combined Challenges of Selectivity and Catalyst Deactivation

The chemoselective, continuous, multistep reduction of iodo-nitroaromatics in a fixed-bed hydrogenation reactor has been investigated. This transformation poses challenges upon both the catalyst and process conditions if high yields are to be achieved. Fi

Continuous Selective Hydrogenation of Refametinib Iodo-nitroaniline Key Intermediate DIM-NA over Raney Cobalt Catalyst at kg/day Scale with Online UV-Visible Conversion Control

The continuous selective hydrogenation of the iodo-nitroaromatic refametinib active pharmaceutical ingredient (API) intermediate (2,3-difluoro-5-methoxy-6-nitro-phenyl)-(2-fluoro-4-iodo-phenyl)-amine (DIM-NA) to the corresponding iodo-aniline 3,4-difluoro-N2-(2-fluoro-4-iodo-phenyl)-6-methoxy-benzene-1,2-diamine (DIM-DAB) was investigated using a conventional Raney cobalt catalyst in a cocurrent trickle-bed reactor. Suitable reaction conditions targeting full conversion and high selectivity, that is, low degrees of hydro-dehalogenation of the labile iodine substituent, were evaluated in investigations employing a short 4 mL screening reactor. The process was then transferred to a longer 40 mL reactor. Raney cobalt was found to be a highly selective catalyst, yielding only very small amounts of the desiodinated aniline desiodo-DIM-DAB or other side products. Productivities up to 144 g/h crude DIM-DAB were achieved operating the 40 mL reactor with a 0.2 M reactant solution in the presence of 3.4 equiv of H2 at 60 °C. Inlet pressure resulting from the flow rate increase was identified as a key parameter for successful throughput maximization. One kilogram of starting material was eventually converted to DIM-DAB in high yield and excellent quality within 8 h runtime. Online monitoring of the UV-vis absorption of the product stream allowed for conversion control and fast detection of process variations. Compared to the available DIM-NA batch reduction procedures, processing in continuous flow proves convincing by the safe implementation and reusability of the Raney type catalyst within a strongly intensified and highly selective process.

HETEROCYCLIC SULFONAMIDE DERIVATIVES

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation).

N-(ARYLAMINO)-SULFONAMIDE INHIBITORS OF MEK

This invention concerns N-(2-arylamino) aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS

This invention concerns N-(ortho phenylaminoaryl), N′-alkyl sulfamides which are inhibitors of MEK and are useful in the treatment of cancer and other hyperproliferative diseases.